[Standards, Options, and Recommendations for brachytherapy in patients with prostate cancer: efficacy and toxicity].
BACKGROUND
The "Standards, Options and Recommendations" (SOR) collaborative project was initiated in 1993 by the Federation of the French Cancer Centres (FNCLCC), with the 20 French Regional Cancer Centres, several French public university and general hospitals, as well as private clinics and medical specialty societies. Its main objective is the development of serviceable clinical practice guidelines in order to improve the quality of health care and the outcome of cancer patients. The methodology is based on a literature review, followed by a critical appraisal by a multidisciplinary group of experts. Draft guidelines are produced, then validated by specialists in cancer care delivery.


OBJECTIVE
Produce clinical practice guidelines for the brachytherapy of prostate cancer using the methodology developed by the Standards, Options and Recommendations project.


METHODS
The FNCLCC and the French Urology Association (AFU) first designated the multidisciplinary group of experts. Available data were collected by a search of Medline and lists selected by experts in the group. A first draft of the guidelines was written, they validated by independent reviewers.


RESULTS
The main recommendations are: 1/Brachytherapy with permanent seeds alone is a possible curative treatment for prostate cancer patients with the following prognosis factors: tumour stage T1 or T2a (TNM 1992), Gleason score < or = 6 and PSA < 10 micrograms/L. 2/Combined treatment with brachytherapy and hormonal therapy could be more efficient than brachytherapy alone for prostate cancer patients with Gleason score > 7 and/or PSA > 10.3/Combination of brachytherapy and external beam radiation therapy can be proposed to prostate cancer patients with intermediate prognosis. 4/Before and after seed implantation, risks of infection must be prevented by appropriate antibiotic therapy (recommendation). 5/Brachytherapy must not be performed within 2 months of transurethral prostate resection. 6/The height of the urethra receiving more than 200% of the prescribed dose must be reported. The portion of the rectum receiving 100 and 120% of the prescribed dose must be limited to 10 and 5 mm length, respectively.
Pommier
P
P
Centre Léon-Bérard, Lyon.
Villers
A
A
Bataillard
A
A
Brune
D
D
Fervers
B
B
Bachaud
J M
JM
Berger
N
N
Bertrand
A F
AF
Bouvier
R
R
Daver
A
A
Fontaine
E
E
Guilloneau
B
B
Haillot
O
O
Lagrange
J L
JL
Molinié
V
V
Muratet
J P
JP
Pabot du Chatelard
P
P
Peneau
M
M
Prapotnitch
D
D
Ravery
V
V
Richaud
P
P
Rossi
D
D
Soret
J Y
JY
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D001918:Brachytherapy / Q000379:methods* / Q000592:standards; D003131:Combined Modality Therapy; D003657:Decision Making; D005602:France; D006801:Humans; D007400:Interprofessional Relations; D008297:Male; D009367:Neoplasm Staging; D017410:Practice Guidelines as Topic; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D011787:Quality of Health Care
D018931:Antineoplastic Agents, Hormonal